Record-Breaking Financial Results
Achieved all-time highs for revenue, operating income, adjusted operating income, and net income. Revenue growth was 13% compared to the previous year, reaching ¥772.2 billion, driven by U.S. growth and foreign exchange effects.
Strong Performance Across Regions
The U.S. saw the highest growth rate among all regions with double-digit growth in local currency terms. Europe and Japan also experienced strong sales driven by demand across various sectors.
Cardiac and Vascular Company Growth
Sales and revenue grew by 8% on a local currency basis, with strong contributions from Neuro and Aortic sectors in the U.S. and China.
Positive Impact of Pricing Measures
Improved profit margins achieved through pricing policies, with positive effects seen from reimbursement price revisions in Japan and price increases overseas.
Expansion in Blood and Cell Technologies
Revenue driven by the plasma innovation business, with the Rika system installed in 70% of plasma collection centers, boosting sales and profitability.